Illumina is leveraging our leadership in next-generation sequencing to deliver in-vitro diagnostic (IVD) solutions to improve the management of cancer patients in the clinic. We are partnering with leading biotechnology companies to develop companion diagnostics for best-in-class therapeutics.
Distributable diagnostic solutions, such as a companion diagnostic (CDx) version of TruSight Tumor 170 and a CDx version of TruSight Oncology 500, used with the NextSeq 550Dx instrument, will enable labs to perform precision medicine testing in-house.
Illumina and Loxo Oncology to Partner on Developing Next-Generation Sequencing-Based Pan-Cancer Companion DiagnosticsView Press Release
Illumina and Bristol-Myers Squibb Announce Strategic Collaboration to Develop and Commercialize Companion Diagnostics for Bristol-Myers Squibb’s Oncology ImmunotherapiesView Press Release
TruSight Tumor 170 is a novel DNA- and RNA-based solution to provide comprehensive variant analysis for solid tumors. With the launch of this product, Illumina has developed the underlying chemistry and workflow to enable a modular and scalable approach to future IVD development in tissue and blood.
This platform, called TruSight Oncology, provides the building blocks for future products in our pipeline. This chemistry platform can be extended to whole-exome and whole-genome sequencing, as well as sequencing RNA transcripts for truly comprehensive profiling of cancers.
We believe that TruSight Oncology will be highly impactful, especially in enabling the development of immunotherapy and circulating tumor DNA (ctDNA) monitoring applications.
“The identification of biomarkers for targeted therapies is emerging as a key part of a cancer patient’s journey, from treatment selection through response monitoring and allows physicians to follow the evolution of a patient’s tumor over time. Next-generation sequencing assays, such as a CDx version of TruSight Oncology 500, are ideally suited to the comprehensive interrogation of a patient’s cancer.”